Ocular manifestations of multiple sclerosis

Current Opinion in Ophthalmology

Volumn 16, Issue 5, 2005, Pages 315-320

  Chen, Ling ^a,c   Gordon, Lynn K ^a,b  

^a JULES STEIN EYE INSTITUTE   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c SHENZHEN EYE HOSPITAL   (China)

Author keywords

Granulomatous; Internuclear ophthalmoplegia; Magnetic resonance imaging; Methylprednisolone; Multiple sclerosis; Nystagmus; Optic neuritis; Pars planitis; Retinal periphlebitis; Retrobulbar neuritis; Uveitis

Indexed keywords

METHYLPREDNISOLONE; PREDNISONE;

DIFFERENTIAL DIAGNOSIS; DIPLOPIA; HUMAN; INFLAMMATORY DISEASE; INTERMEDIATE UVEITIS; INTERNUCLEAR OPHTHALMOPLEGIA; LYME DISEASE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OPTIC NERVE DISEASE; OSCILLOPSIA; PHLEBITIS; POSTVIRAL FATIGUE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOIDOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

EYE DISEASES; HUMANS; MULTIPLE SCLEROSIS;

EID: 25844491652     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000179804.49842.e2     Document Type: Review

References (60)

1. Hafler DA, Slavik JM, Anderson DE, et al. Multiple sclerosis. Immunol Rev 2005; 204:208-231. This paper is a thorough review of current thoughts regarding immunopathogenesis of MS and of novel therapeutics in control of disease. In addition it discusses the recent advances in genetic investigations in MS.
2. Ruggieri M, Iannetti P, Polizzi A, et al. Multiple sclerosis in children under 10 years of age. Neurol Sci 2004; 25(Suppl 4):S326-S335.
3. Jacobs DA, Galetta SL. Multiple sclerosis and the visual system. Ophthalmol Clin North Am 2004; 17:265-273. The authors present a cogent discussion about the neuro-ophthalmic manifestations of MS including a thorough review of the different abnormalities in motility. In particular the discussions regarding the acute management of optic neuritis and evaluation of the national prospective immunomodulatory therapy provide important information.
4. Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111-121. The authors provide another well written and thorough review of neuro-ophthalmologic signs and symptoms in MS.
5. Boomer JA, Siatkowski RM. Optic neuritis in adults and children. Semin Ophthalmol 2003; 18:174-180.
6. Triulzi F. Neuroradiology of multiple sclerosis in children. Neurol Sci 2004; 25(Suppl 4):S340-S343.
7. Mizota A, Niimura M, Adachi-Usami E. Clinical characteristics of Japanese children with optic neuritis. Pediatr Neurol 2004; 31:42-45.
8. Shiraishi K, Higuchi Y, Ozawa K, et al. Clinical course and prognosis of 27 patients with childhood onset multiple sclerosis in Japan. Brain Dev 2005; 27:224-227. This is an important review of 58 patients with MS in whom the disease onset was prior to age 16 years.
9. Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am J Ophthalmol 2005; 139:1101-1108. This paper is a comprehensive review of therapeutic options in MS and in particular the controversies and consideration in initiating therapy for patients with optic neuritis.
10. Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol 2002; 13:375-380.
11. Protti A, Spreafico C, Frigerio R, et al. Optic neuritis: diagnostic criteria application in clinical practice. Neurol Sci 2004; 25(Suppl 3):S296-S297.
12. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4:281-288. This review details features of clinically isolated syndromes associated with a systemic diagnosis of MS. The authors detail optic neuritis as a clinically isolated syndrome in comparison with other manifestations of neurologic impairment.
13. Agostoni E, Frigerio R, Protti A. Controversies in optic neuritis pain diagnosis. Neurol Sci 2005; 26(Suppl 2):s75-s78.
14. Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991; 109:1673-1678.
15. Keltner JL, Johnson CA, Spurr JO, Beck RW. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1993; 111:231-234.
16. Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis: one-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol 1994; 112:946-953.
17. Racette L, Sample PA. Short-wavelength automated perimetry. Ophthalmol Clin North Am 2003; 16:227-236.
18. Nilsson P, Larsson EM, Maly-Sundgren P, et al. Predicting the outcome of optic neuritis evaluation of risk factors after 30 years of follow-up. J Neurol 2005; 252:396-402. This paper provides the long-term (31-year) follow-up of 86 patients with optic neuritis and details the relapse rates and conversion to MS.
19. Eggenberger E. Inflammatory optic neuropathies. Ophthalmol Clin North Am 2001; 14:73-82.
20. Williams KE, Johnson LN. Neuroretinitis in patients with multiple sclerosis. Ophthalmology 2004; 111:335-340.
21. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. Lancet Neurol 2005; 4:341-348. This paper discusses new insights from functional imaging studies as well as therapeutic choices in the treatment of patients with MS.
22. Sisto D, Trojano M, Vetrugno M, et al. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci 2005; 46:1264-1268. The comparison of multiple examinations could help detect subclinical visual involvement in patients with MS.
23. Hickman SJ, Miszkiel KA, Plant GT, Miller DH. The optic nerve sheath on MRI in acute optic neuritis. Neuroradiology 2005; 47:51-55.
24. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg 2004; 106:147-158.
25. Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol 2003; 121:944-949.
26. Eggenberger ER, Beck RW, Gal RL, et al. Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Optic Neuritis Study Group. Arch Neurol 2004; 61: 1538-1541. Long-term follow-up data revealed that MRI abnormalities may accumulate without causing any clinical manifestations of MS.
27. Candler PM, Dale RC. Three cases of central nervous system complications associated with Mycoplasma pneumoniae. Pediatr Neurol 2004; 31:133-138.
28. Gilden DH. Infectious causes of multiple sclerosis. Lancet Neurol 2005; 4: 195-202.
29. Preechawat P, Poonyathalang A. Bilateral optic neuritis after dengue viral infection. J Neuroophthalmol 2005; 25:51-52.
30. Garg S, Jampol LM. Systemic and intraocular manifestations of West Nile virus infection. Surv Ophthalmol 2005; 50:3-13.
31. Ginestal RC, Plaza JF, Callejo JM, et al. Bilateral optic neuritis and Guillain-Barre syndrome following an acute Mycoplasma pneumoniae infection. J Neurol 2004; 251:767-768.
32. Monteiro ML, Borges WI, do Val Ferreira RC, et al. Bilateral optic neuritis in Wegener granulomatosis. J Neuroophthalmol 2005; 25:25-28.
33. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet 2002; 360:1953-1962.
34. McCluskey PJ, Watson PG, Lightman S, et al. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology 1999; 106:2380-2386.
35. Rizzo JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Arch Ophthalmol 1991; 109:1668-1672.
36. Beck RW, Gal RL, Bhatti MT. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol 2004; 137:77-83. Long-term follow-up data revealed that the majority of patients with demyelinating optic neuritis had an excellent visual prognosis.
37. Pirko I, Blauwet LK, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Arch Neurol 2004; 61:1401-1405.
38. Jackson TL, Ong GL, Ripley LG. Orientational contrast sensitivity and chromatic contrast thresholds. Am J Ophthalmol 2004; 137:283-286.
39. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005; 64:992-995. Low-contrast letter acuity testing provided information relevant to the disease process in patients with MS.
40. Rieckmann P, Toyka KV, Bassetti C, et al. Escalating immunotherapy of multiple sclerosis: new aspects and practical application. J Neurol 2004; 251: 1329-1339. A comprehensive review of immunotherapy for MS.
41. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581-588.
42. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005; 64:804-810.
43. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004; 63:1081-1083.
44. Diem R, Sattler MB, Merkler D, et al. Combined therapy with methylprednisolone and erythropoietin in a model. Brain 2005; 128:375-385.
45. Beck RW, Smith CH, Gal RL, et al. Neurologic impairment 10 years after optic neuritis. Arch Neurol 2004; 61:1386-1389. Ten-year follow-up data suggest that the majority of patients with MS have a benign course.
46. Tsuda H, Ishikawa H, Matsunaga H, Mizutani T. A neuro-ophthalmological analysis in 80 cases of multiple sclerosis [in Japanese]. Rinsho Shinkeigaku 2004; 44:513-521.
47. Smith RM, Oommen BS, Stahl JS. Application of adaptive filters to visual testing and treatment in acquired pendular nystagmus. J Rehabil Res Dev 2004; 41:313-324.
48. Bolanos I, Lozano D, Cantu C. Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients. Acta Neurol Scand 2004; 110:161-165.
49. Keane JR. Internuclear ophthalmoplegia: unusual causes in 114 of 410 patients. Arch Neurol 2005; 62:714-717. The author summarizes the causes of INO, which merit serious consideration in differential diagnosis.
50. Frohman TC, Frohman EM, O'Suilleabhain P, et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology 2003; 61:848-850.
51. Smith JR, Rosenbaum JT. Neurological concomitants of uveitis. Br J Ophthalmol 2004; 88:1498-1499.
52. Biousse V, Trichet C, Bloch-Michel E, Roullet E. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 1999; 52:179-181.
53. Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul Immunol Inflamm 2004; 12:137-142.
54. Raja SC, Jabs DA, Dunn JP, et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology 1999; 106:594-599.
55. Towler HM, Lightman S. Symptomatic intraocular inflammation in multiple sclerosis. Clin Experiment Ophthalmol 2000; 28:97-102.
56. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16:183-200.
57. Gordon LK. Uveitis and neurological diseases. Br J Ophthalmol 2004; 88: 1483-1484.
58. Tola MR, Granieri E, Casetta I, et al. Retinal periphlebitis in multiple-sclerosis: a marker of disease-activity. Eur Neurol 1993; 33:93-96.
59. Patte M, Rouher FN, Vernay D, et al. Proliferative retinal vasculitis and multiple sclerosis: a case report. J Fr Ophtalmol 2003; 26:381-385.
60. Ronzani M, Lang GE, Wagner P, Lang GK. Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ger J Ophthalmol 1995; 4:328-331.